Rucaparib for PARP inhibitor-pretreated ovarian cancer: A GEICO retrospective subgroup analysis from the Spanish Rucaparib Access Program

• Asıl Yazarlar: Alfonso Yubero (Yazar), Purificación Estévez (Yazar), Aránzazu Barquín (Yazar), Luisa Sánchez (Yazar), Ana Santaballa (Yazar), Bella Pajares (Yazar), Piedad Reche (Yazar), Carmen Salvador (Yazar), Luis Manso (Yazar), Raúl Márquez (Yazar), Antonio González-Martín (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Elsevier, 2023-08-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

The poly(ADP-ribose) polymerase inhibitor (PARPi) rucaparib is approved as maintenance therapy for patients with platinum-sensitive recurrent high-grade ovarian cancer (HGOC). The efficacy and safety of rucaparib after PARPi therapy are largely unknown; therefore, we analyzed outcomes in the subgrou...